Seeking Alpha

Galena Biopharma (GALE) +7.8% premarket after saying studies of its NeuVax treatment continue to...

Galena Biopharma (GALE) +7.8% premarket after saying studies of its NeuVax treatment continue to demonstrate excellent safety and efficacy profiles.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|